Erratum to: Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery (International Orthopaedics (DOI: 10.1007/s00264-011-1393-5));Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement

International Orthopaedics

Volumn 36, Issue 4, 2012, Pages 741-748

  Dahl, Ola E ^a,b   Kurth, Andreas A ^c   Rosencher, Nadia ^d   Noack, Herbert ^e   Clemens, Andreas ^e   Eriksson, Bengt I ^f  

^a Elverum Central Hospital   (Norway)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; ENOXAPARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; N ((2 (((4 (AMINOIMINOMETHYL)PHENYL)AMINO)METHYL) 1 METHYL 1H BENZIMIDAZOL 5 YL)CARBONYL) N 2 PYRIDINYL BETA ALANINE; N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-BETA-ALANINE;

ABSCESS; AGED; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; HIP ARTHROPLASTY; HUMAN; KIDNEY FAILURE; KNEE ARTHROPLASTY; LEG THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURGICAL WOUND; THROMBOSIS PREVENTION; WOUND HEALING IMPAIRMENT; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOEMBOLISM;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; BLOOD LOSS, SURGICAL; DOUBLE-BLIND METHOD; ENOXAPARIN; FIBRINOLYTIC AGENTS; HUMANS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; VENOUS THROMBOEMBOLISM;

EID: 84859156077     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-012-1492-y     Document Type: Erratum

References (34)

1. Dahl OE (2004) Orthopaedic surgery as a model for drug development in thrombosis. Drugs 64(Suppl 1):17-25
2. Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW; EXULT B Study Group (2005) Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 87:2169-2177 (Pubitemid 41407539)
3. Eriksson BI, Kakkar AK, Turpie AG, GentM, Bandel TJ, Homering M, Misselwitz F, Lassen MR (2009) Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 91:636-644
4. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:257S-298S
5. Pola E, Papaleo P, Santoliquido A, Gasparini G, Aulisa L, De Santis E (2004) Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing total hip arthroplasty. J Bone Joint Surg Am 86-A:57-61 (Pubitemid 38057337)
6. McNally MA, Mollan RA (1993) Venous thromboembolism and orthopaedic surgery. J Bone Joint Surg Br 75:517-519 (Pubitemid 23222119)
7. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:381S-453S
8. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL (2002) Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 96:1140-1146 (Pubitemid 34462575)
9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR, Study Group RE-MODEL (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178-2185 (Pubitemid 47617868)
11. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group (2007) Dabigatran etexilate vs enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949-956 (Pubitemid 47393577)
12. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, Study Group RE-NOVATEII (2011) Oral dabigatran vs enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105:721-729
13. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1-9
14. European Medicines Agency (2011). Pradaxa - Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR--- Product-Information/human/000829/ WC500041059.pdf. Accessed 16 September 2011
15. The European Agency for the Evaluation of Medicinal Products (2007) http://www.emea.europa.eu/pdfs/human/ewp/70798en-fin. pdf. Accessed 16 March 2011
16. Dahl OE, Borris LC, Bergqvist D, Schnack RM, Eriksson BI, Kakkar AK, Colwell CW, Caprini JA, Fletcher J, Friedman RJ, Lassen MR, Frostick SP, Sakon M, Kwong LM, Kakkar VV; International Surgical Thrombosis Forum (2008) Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use. Int Angiol 27:60-67
17. Hull RD, Yusen RD, Bergqvist D (2009) State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 15:377-388
18. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P; BISTRO II Study Group (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3:103-111 (Pubitemid 41647122)
19. Ginzburg E, Dujardin F (2011) Physicians' perceptions of the definition of major bleeding in major orthopaedic surgery; results of an international survey. J Thromb Thrombolysis 31:188-195
20. Dahl OE, Bergqvist D (2002) Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med 8:394-397 (Pubitemid 34836943)
21. Colwell CW Jr, Spiro TE (1995) Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop Relat Res 319:215-222
22. European Medicines Agency (2007) Fondaparinux summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR--- Product-Information/human/000403/ WC500027746.pdf. Accessed 16 March 2011
23. Turpie AG, Lensing AW, Fuji T, Boyle DA (2009) Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 20:114-121
24. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group (2008) Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 168:1805-1812
25. Gouin-Thibault I, Pautas E, Siguret V (2005) Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 28:333-349 (Pubitemid 40545768)
26. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF (2000) Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20:771-775 (Pubitemid 30457356)
27. sanofi-aventis US LLC (2009) Lovenox Prescribing Information. http://products.sanofi-aventis.us/lovenox/lovenox.html#8.5. Accessed 16 March 2011
28. Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G (2009) Interpretation of benefit-risk of enoxaparin as comparator in the RECORD Program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 15:389-394
29. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M (1986) A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315:925-929 (Pubitemid 16023679)
30. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y (1996) Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin vs placebo. Lancet 348:224-228 (Pubitemid 26254196)
31. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG; Steering Committee of the Pentasaccharide in Hip-fracture Surgery Group (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298-1304
32. Saleh K, Olson M, Resig S, Bershadsky B, Kuskowski M, Gioe T, Robinson H, Schmidt R, McElfresh E (2002) Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. J Orthop Res 20:506-515 (Pubitemid 34464075)
33. Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE (2007) Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am 89:33-38 (Pubitemid 46059142)
34. Bonneux IM, Bellemans J, Fabry G (2006) Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin. Knee 13:118-121 (Pubitemid 43374935)